Advertisement

Adding Targeted Therapy to Chemoimmunotherapy May Offer Long-Term Benefits for Patients With IGHV-Mutated CLL


Advertisement
Get Permission

In a phase II study, researchers evaluated the efficacy of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab—a chemoimmunotherapy and targeted therapy combination—in 45 previously untreated patients with IGHV-mutated chronic lymphocytic leukemia (CLL). Nitin Jain, MD, of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, and colleagues reported the long-term outcomes of the study (after a median follow-up of 56.8 months) at the European Hematology Association (EHA) 2022 Congress (Abstract S149).

Nitin Jain, MD

Nitin Jain, MD

After just three cycles, 87% of patients had undetectable measurable residual disease, with improved responses after continued therapy. The 5-year progression-free survival and overall survival rates were 97.7% and 97.8%, respectively. One patient had CLL progression, and no patients had Richter’s transformation.

The findings reveal that ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab offers high rates of undetectable measurable residual disease remission and long-term survival with only three cycles of chemotherapy, as opposed to previous treatments with six cycles of chemotherapy.

Disclosure: For full disclosures of the study authors, visit library.ehaweb.org.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
Advertisement

Advertisement



Advertisement